Statins are the cornerstone of modern cardiovascular prevention, widely recognised for their potent LDL-cholesterol–lowering effects and their broader influence on endothelial health, inflammation and plaque stability. As clinical guidelines continue to evolve and incorporate coronary calcium scoring, non-statin agents and personalised risk assessment, many clinicians search for updated insights on Statins when selecting preventive or lipid-management tracks at a cardiology conference. Because statins remain central to long-term lipid-lowering therapy, this session explores their mechanisms, clinical applications, safety considerations and the expanding role they play alongside newer therapeutic options.

The session begins with an in-depth explanation of how statins inhibit HMG-CoA reductase to reduce hepatic cholesterol synthesis, upregulate LDL receptors and accelerate clearance of atherogenic particles. Participants review the differences between hydrophilic and lipophilic statins, high- vs. moderate-intensity regimens, and how pharmacokinetics influence drug selection in patients with comorbidities such as metabolic syndrome, diabetes or chronic kidney disease. Real-world considerations—including cost, availability, dose titration and drug–drug interactions—are integrated into practical prescribing guidance.

A major emphasis is placed on clinical evidence. The session summarises landmark trials demonstrating risk reductions in myocardial infarction, stroke, cardiovascular death and the need for revascularisation. Special attention is given to high-risk groups including patients with established atherosclerotic cardiovascular disease, familial hypercholesterolemia, diabetes and those with elevated lipoprotein(a). Participants examine the role of statins in secondary prevention, post-PCI therapy, post-CABG management and stabilisation of vulnerable plaque.

Addressing statin intolerance is a key focus. Clinicians learn structured evaluation methods for muscle symptoms, liver enzyme elevations and perceived side effects. Strategies such as rechallenge protocols, alternate dosing, switching statin class and incorporating combination therapy are discussed with the goal of maintaining lipid control without compromising patient comfort or adherence. The session also clarifies misconceptions about statins and explores communication strategies for addressing patient hesitancy.

Non-statin therapies—including ezetimibe, bempedoic acid and PCSK9 inhibitors—are discussed in the context of combination therapy. Attendees learn when to escalate treatment beyond statins, guided by quantitative LDL thresholds, calcium scores and global risk assessment. Case examples illustrate how to individualise therapy using guideline-directed approaches and shared decision-making.

Future directions include genetic predictors of statin responsiveness, precision lipidology, AI-based risk algorithms and long-acting injectable agents that may complement or replace current regimens. By the end of the session, clinicians will be equipped with a practical, evidence-driven understanding of statins, enabling them to prescribe confidently, manage intolerance effectively and integrate lipid control into holistic cardiovascular prevention strategies.